Protocol Ledger

NCT06006247 · Phase II · COMPLETED

Early Parkinson's Disease Monotherapy With CVN424

Interventional Phase II clinical trial protocol NCT06006247 sponsored by Cerevance Beta in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-11 Enrollment: 64 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06006247
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)64 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06006247
Protocol FieldVerified Registry Value
NCT IdentifierNCT06006247
Consolidated Lead SponsorCerevance Beta
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment64 participants (ACTUAL)
Registered Start Date2023-09-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06006247
Hospital Research SiteLocationSite Profile
University of Alabama at BirminghamBirmingham, ALOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI